Ecaterina E. Dumbrava

Author

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

E Dumbravă, E E Ileana Dumbrava, E. Dumbrava, E.E. Dumbrava, E.E. Ileana Dumbrava, Ecaterina Dumbrava, Ecaterina E Dumbrava, Ecaterina E Ileana Dumbrava, Ecaterina E. Dumbrava, Ecaterina E. Dumbrava, MD

334

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Columbia University Irving Medical Center Dana-Farber Cancer Institute Sarah Cannon

About

Ecaterina E. Dumbrava is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	17	798
2	Immunology	7	7	164
3	Cell Biology	4	4	132
4	Health Sciences	1	1	44
5	Biochemistry	1	1	335

Ecaterina E. Dumbrava

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials Timothy A. Yap, Naval Daver, Mikhila Mahendra, Nature Medicine Hematological MalignancyOncologyBiochemistryMedicineAcute Myeloid Leukemia	2023	335
Phase 2 study of pembrolizumab in patients with advanced rare cancers Aung Naing, Funda Meric‐Bernstam, Bettzy Stephen, Journal for ImmunoTherapy of Cancer	2020	127
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring <i>CCNE1</i> Amplification Siqing Fu, Shuyang Yao, Yuan Yuan, Journal of Clinical Oncology	2022	84
First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a <i>TP53</i> Y220C mutation. Ecaterina E. Dumbrava, Melissa L. Johnson, Anthony W. Tolcher, Journal of Clinical Oncology Spontaneous MutationMolecular BiologyPathologyP53 ProteinPreliminary Efficacy	2022	77
Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. Timothy A. Yap, Jordi Rodón, Sarina A. Piha‐Paul, Journal of Clinical Oncology PathologyAdvanced Solid TumorsTumor BiologyOncologyCancer Cell Biology	2019	66
HER2-low expression in patients with advanced or metastatic solid tumors Burak Uzunparmak, Cara Haymaker, Gabriela Raso, Annals of Oncology Breast OncologyMalignant DiseaseMedicinePathologyHer2-low Expression	2023	63
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies Aparna Hegde, Priyamvada Jayaprakash, Coline A. Couillault, Clinical Cancer Research	2021	58
Targeting <i>ERBB2</i> ( <i>HER2</i> ) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications Ecaterina E. Dumbrava, Kavitha Balaji, Kanwal Raghav, JCO Precision Oncology	2019	49
Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. Manish Sharma, Richard D. Carvajal, Glenn J. Hanna, Journal of Clinical Oncology Innate Immune SystemImmunologyImmunoeditingImmunotherapeuticsImmunotherapy	2021	44
A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors. Bob T. Li, Mark D. Pegram, Keun‐Wook Lee, Journal of Clinical Oncology Bdc-1001 ExposureImmunologyImmunoeditingImmunotherapeuticsImmunotherapy	2023	40

Page 1